VACC - Vaccitech plc Stock Price, Fair Value and News

3.41USD-0.11 (-3.13%)Delayed

Market Summary

USD3.41-0.11

Delayed

-3.13%

VACC Stock Price

View Fullscreen

VACC RSI Chart

VACC Valuation

Market Cap

144.0M

Price/Earnings (Trailing)

-2.04

Price/Sales (Trailing)

179.59

EV/EBITDA

-0.21

Price/Free Cashflow

-2.29

VACC Price/Sales (Trailing)

VACC Profitability

EBT Margin

-9144.64%

Return on Equity

-41.07%

Return on Assets

-35.41%

Free Cashflow Yield

-43.59%

VACC Fundamentals

VACC Revenue

Revenue (TTM)

802.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

VACC Earnings

Earnings (TTM)

-70.6M

Earnings Growth (Yr)

15%

Earnings Growth (Qtr)

10.26%

Breaking Down VACC Revenue

Last 7 days

-4.6%

Last 30 days

11.8%

Last 90 days

3.8%

Trailing 12 Months

49.8%

How does VACC drawdown profile look like?

VACC Financial Health

Current Ratio

11.15

VACC Investor Care

Shares Dilution (1Y)

1.73%

Diluted EPS (TTM)

-1.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	33.7M	22.8M	11.8M	802.0K
2022	18.3M	27.1M	35.9M	44.7M
2021	4.3M	3.9M	623.0K	9.4M
2020	0	0	0	4.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaccitech plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 26, 2023	scheeren joseph	bought	24,400	2.44	10,000	-
May 25, 2023	wright robin	bought	36,612	2.6627	13,750	-
Mar 27, 2023	enright william	sold	-36,298	2.4199	-15,000	chief executive officer
Sep 30, 2022	m&g alternatives investment management ltd	sold	-	-	-4,108,750	-
Sep 30, 2022	m&g investment management ltd	acquired	-	-	4,108,750	-
Aug 25, 2022	ellis christopher	acquired	15.6704	0.0004	39,176	chief operating officer
Aug 25, 2022	ellis christopher	sold	-257,396	6.57024	-39,176	chief operating officer
Aug 25, 2022	griffiths graham	sold	-73,870	7.387	-10,000	chief business officer
Aug 24, 2022	ellis christopher	acquired	0.18	0.0004	450	chief operating officer
Aug 24, 2022	ellis christopher	sold	-2,152	4.7827	-450	chief operating officer

Which funds bought or sold VACC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-21.89	-30,151	30,612	-%
May 15, 2024	Johns Hopkins University	added	13.22	-107,000	291,000	0.01%
May 15, 2024	BlueCrest Capital Management Ltd	unchanged	-	-710,901	1,291,560	0.06%
May 15, 2024	HSG Holding Ltd	unchanged	-	-681,827	3,622,210	0.34%
May 14, 2024	DC Funds, LP	unchanged	-	-841,287	1,528,450	14.77%
May 14, 2024	Baird Financial Group, Inc.	reduced	-14.57	-325,194	399,138	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-6.73	-44,000	66,000	-%
May 13, 2024	UBS Group AG	unchanged	-	-2,026	3,682	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-13,419	27,763	-%
May 10, 2024	M&G Plc	new	-	10,394,700	10,394,700	0.04%

Are Funds Buying or Selling VACC?

Are funds buying VACC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VACC

No. of Funds

Unveiling Vaccitech plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	m&g investment management ltd	13.48%	5,197,349	SC 13G/A
Jan 20, 2023	m&g investment management ltd	13.94%	5,197,349	SC 13G/A
Oct 07, 2022	m&g investment management ltd	13.97%	5,197,349	SC 13G
Feb 11, 2022	oxford science enterprises plc	25.22%	0	SC 13G

Recent SEC filings of Vaccitech plc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	8-K/A	Current Report
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report

Peers (Alternatives to Vaccitech plc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vaccitech plc News

Latest updates

Vaccitech plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-	-	-	167,000	334,000	3,395,500	6,457,000	6,165,000	17,063,000	15,018,000	7,518,500	19,000	35,000	215,000	354,000	3,251,000	511,000	705,000
Operating Expenses	-14.4%	17,119,000	19,988,000	16,105,000	26,671,000	21,952,000	31,586,500	-1,071,000	3,828,000	14,364,000	16,667,000	5,555,000	16,880,000	6,387,000	9,987,000	4,679,000	4,847,000	5,354,000
S&GA Expenses	-	-	-	-	-	12,138,000	-	-	-	3,663,000	9,786,000	1,184,000	12,371,000	1,777,000	7,421,000	977,000	970,000	1,112,000
R&D Expenses	74.6%	11,125,000	6,373,000	15,144,000	13,543,000	9,814,000	12,185,000	9,744,000	9,720,000	10,701,000	6,881,000	4,371,000	4,509,000	4,610,000	2,566,000	3,702,000	3,877,000	4,242,000
EBITDA Margin	4.8%	-84.38	-88.61	-6.49	-2.39	-0.45	0.12	-1.18	-1.60	-2.72	-5.07	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	49,000	-7,000	-14,000	-	-21,500	11,000	-7,000	74,000	5,318,000	-	-5,300,000	2,650,000	-	969,000	-	-
Income Taxes	95.5%	-37,000	-820,000	-603,000	-1,136,000	-516,000	-2,019,000	-674,000	-915,000	-863,000	32,000	-7,000	12,000	-65,000	-	-	-	-
Earnings Before Taxes	14.1%	-15,557,000	-18,110,000	-14,713,000	-24,960,000	-18,739,000	-23,182,000	7,547,000	14,774,000	1,711,000	-	-	-	-	-	-	-	-
EBT Margin	4.2%	-91.45	-95.41	-6.93	-2.61	-0.58	0.02	-1.43	-1.89	-2.80	-5.42	-	-	-	-	-	-	-
Net Income	10.3%	-15,489,000	-17,260,500	-14,072,000	-23,824,000	-18,223,000	-21,176,000	8,242,000	15,689,000	2,574,000	-15,025,000	-4,557,000	-15,985,000	-15,386,000	-10,355,500	158,000	-3,657,000	-3,951,000
Net Income Margin	3.7%	-88.09	-91.50	-6.56	-2.42	-0.46	0.12	0.32	-0.05	-1.81	-5.40	-74.29	-10.78	-6.75	-	-	-	-
Free Cashflow	37.6%	-12,130,000	-19,450,000	-11,227,000	-19,980,000	-5,681,000	-11,929,000	9,478,000	-10,447,000	-7,671,000	-8,396,000	-2,146,000	-14,826,000	-8,361,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-7.0%	199	215	230	246	262	270	275	285	286	281	257	260	166	51.00
Current Assets	-8.8%	143	157	171	185	201	213	219	226	231	227	246	257	163	48.00
Cash Equivalents	-8.5%	130	142	160	173	191	194	200	192	201	214	234	244	156	43.00
Net PPE	-2.4%	12.00	12.00	12.00	14.00	13.00	8.00	7.00	7.00	5.00	2.00	1.00	1.00	1.00	1.00
Goodwill	0%	12.00	12.00	12.00	12.00	12.00	12.00	13.00	13.00	13.00	13.00	-	-	-	-
Liabilities	-0.2%	27.00	28.00	34.00	29.00	28.00	27.00	31.00	30.00	33.00	28.00	14.00	10.00	10.00	54.00
Current Liabilities	1.9%	13.00	13.00	19.00	12.00	12.00	12.00	14.00	12.00	16.00	11.00	6.00	9.00	9.00	8.00
Shareholder's Equity	-7.9%	172	187	195	217	234	243	244	255	253	253	242	250	-	-
Retained Earnings	-8.8%	-192	-176	-159	-145	-121	-103	-82.05	-90.30	-105	-108	-93.47	-88.91	-72.99	-57.72
Additional Paid-In Capital	0.5%	389	387	386	386	384	380	377	376	373	369	344	341	22.00	22.00
Shares Outstanding	0.8%	39.00	39.00	39.00	39.00	38.00	38.00	37.00	37.00	37.00	37.00	35.00	17.00	8.00	-
Minority Interest	-13.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00
Float	-	-	-	-	79.00	-	-	-	166	-	-	-	404	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	39.7%	-11,822	-19,603	-11,191	-16,957	-3,174	-11,343	11,884	-8,393	-6,579	-7,972	-2,018	-14,624	-7,969	-4,896	-861	-950	-4,321
Share Based Compensation	105.5%	1,615	786	57.00	1,990	2,222	2,041	1,104	2,748	3,984	3,580	3,374	8,736	797	2,200	154	415	856
Cashflow From Investing	-301.3%	-308	153	-36.00	-3,023	-2,507	-586	-2,018	-2,054	-1,092	-12,190	-128	-202	-392	-195	-30.00	-46.00	-22.00
Cashflow From Financing	361.5%	503	109	46.00	28.00	1,689	484	-	-	-159	9.00	-1,387	102,305	121,815	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VACC Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Total revenue

$ 0

$ 468

Operating expenses

Research and development

11,125

9,814

General and administrative

5,994

12,138

Total operating expenses

17,119

21,952

Other operating income

205

Loss from operations

(16,914)

(21,484)

Other income/(expense):

Interest income

775

1,588

Interest expense

(12)

Research and development incentives

594

1,157

Total other income, net

1,357

2,745

Loss before income tax

(15,557)

(18,739)

Tax benefit

516

Net loss

(15,520)

(18,223)

Net loss attributable to noncontrolling interest

Net loss attributable to Barinthus Biotherapeutics plc shareholders

$ (15,489)

$ (18,180)

Weighted-average ordinary shares outstanding, basic (in shares)

38,773,482

38,013,399

Weighted-average ordinary shares outstanding, diluted (in shares)

38,773,482

38,013,399

Net loss per share attributable to ordinary shareholders, basic (in usd per share)

$ (0.40)

$ (0.48)

Net loss per share attributable to ordinary shareholders, diluted (in usd per share)

$ (0.40)

$ (0.48)

Net loss

$ (15,520)

$ (18,223)

Other comprehensive (loss)/gain – foreign currency translation adjustments

(1,577)

4,580

Comprehensive loss

(17,097)

(13,643)

Comprehensive loss attributable to noncontrolling interest

Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders

(17,069)

(13,606)

License revenue

Total revenue

^[1]

$ 0

$ 468

[1]	Includes license revenue from related parties for the three months ended March 31, 2024 and 2023 of nil and $0.5 million, respectively.

VACC Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash, cash equivalents and restricted cash	$ 129,971	$ 142,090
Research and development incentives receivable	5,196	4,908
Prepaid expenses and other current assets	7,964	9,907
Total current assets	143,131	156,905
Goodwill	12,209	12,209
Property and equipment, net	11,532	11,821
Intangible assets, net	24,317	25,108
Right of use assets, net	7,408	7,581
Other assets	885	882
Total assets	199,482	214,506
Current liabilities:
Accounts payable	1,162	1,601
Accrued expenses and other current liabilities	8,330	9,212
Deferred income	1,434	0
Operating lease liability - current	1,909	1,785
Total current liabilities	12,835	12,598
Non-Current liabilities:
Operating lease liability - non-current	10,897	11,191
Contingent consideration	1,867	1,823
Other non-current liabilities	1,330	1,325
Deferred tax liability, net	537	574
Total liabilities	27,466	27,511
Commitments and contingencies (Note 15)
Stockholders’ equity:
Ordinary shares, £0.000025 nominal value; 38,952,956 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding:38,643,540)	1	1
Additional paid-in capital	388,720	386,602
Accumulated deficit	(192,079)	(176,590)
Accumulated other comprehensive loss – foreign currency translation adjustments	(24,895)	(23,315)
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders	171,833	186,784
Noncontrolling interest	183	211
Total stockholders’ equity	172,016	186,995
Total liabilities and stockholders’ equity	199,482	214,506
Deferred A shares
Stockholders’ equity:
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding: 63,443)	$ 86	$ 86

About Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

CEO	Mr. William J. Enright MBA
WEBSITE	vaccitech.co.uk
INDUSTRY	Biotechnology
EMPLOYEES	33

Vaccitech plc Frequently Asked Questions

What is the ticker symbol for Vaccitech plc? What does VACC stand for in stocks?

VACC is the stock ticker symbol of Vaccitech plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaccitech plc (VACC)?

As of Tue Apr 30 2024, market cap of Vaccitech plc is 144.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VACC stock?

You can check VACC's fair value in chart for subscribers.

What is the fair value of VACC stock?

You can check VACC's fair value in chart for subscribers. The fair value of Vaccitech plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaccitech plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VACC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaccitech plc a good stock to buy?

The fair value guage provides a quick view whether VACC is over valued or under valued. Whether Vaccitech plc is cheap or expensive depends on the assumptions which impact Vaccitech plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VACC.

What is Vaccitech plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, VACC's PE ratio (Price to Earnings) is -2.04 and Price to Sales (PS) ratio is 179.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VACC PE ratio will change depending on the future growth rate expectations of investors.